Health News

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that the Marketing Authorisation Application (MAA) for Glybera(R) remains on schedule following meetings with the European Medicine Agency (EMA) concerning the Day 120 List of Questions. The company is confident that Glybera(R), a gene therapy product for lipoprotein lipase deficiency (LPLD), remains on track for a regulatory decision by mid-2011.

Read more

Filed under: Pharmacy News
Tags: gene, medicine, Pharmacy

Related posts

• Wyeth and Santaris Pharma to collaborate on RNA-based medicines (0)
  Wyeth Pharmaceuticals, a division of Wyeth, and Santaris Pharma have announced that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma's proprietary Locked Nucleic Acid (LNA) drug platform, which allows specific targeting and regulation of microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means [...]
  
  
• Study links loss of PTEN gene with patient’s response to melanoma therapy (0)
  Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the [...]
  
  
• Senesco Announces H1N1 Influenza Survival Test Results In Mice (0)
  Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) reported results of H1N1 mouse influenza survival studies that were conducted in Dr. William Scheld's lab at the University of Virginia School of Medicine. Mice treated with an siRNA against Senesco's Factor 5A gene had a 52% survival rate as opposed to a [...]
  
  
• Scientists Rediscover Gene Target For Cancer Therapy (0)
  Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies... Read [...]
  
  
• Research Published In Science Translational Medicine Underscores Value Of Depression Gene Therapy License Held By Neurologix (0)
  Neurologix, Inc. (OTC Bulletin Board: NRGX) announced that a landmark paper, published on October 20th in Science Translational Medicine demonstrating the importance of the p11 gene in modulating depression in mice, utilized a gene therapy approach to reverse depression in mice for which the Company holds exclusive development rights... Read more [tags] Pharmacy News [/tags]